Radiosensitivity of human ovarian carcinoma and melanoma cells to γ-rays and protons

Keta, Otilija; Todorović, D. M.; Popović, Nataša; Korićanac, Lela; Cuttone, G.; Petrović, Ivana

doi:10.5114/aoms.2014.43751

Cited by 11 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These restrictions excluded 84 points from the original set of 369 data points. Data removed due to the restriction of (α/β) x < 30 Gy included all the reported measurements in some studies (Ristic-Fira et al 2011, Petrović et al 2010, Antoccia et al 2009, Sakamoto et al 1980, Keta et al 2014) or the removal of selected data points (Belli et al 2000, Bettega et al 2000, Blomquist et al 1993, Grosse et al 2014, Baggio et al 2002, Schettino et al 2001, Urano et al 1980). The restriction of LET d < 20 keV/μm excluded another two studies (Goodhead et al 1992, Wéra et al 2011) as well as selected data points from other studies (Belli et al 1989, 1992, 1993, 1998, 2000, Bettega et al 1998, Chaudhary et al 2014, Fiorini et al 2011, Folkard et al 1989, Ogheri et al 1997, Prise et al 1990, Schettino et al 2001, Schuff et al 2002, Sgura et al 2000).…”

Section: Methodsmentioning

confidence: 99%

A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all publishedin vitrocell survival data

2015

View full text Add to dashboard Cite

Purpose Proton therapy treatments are currently planned and delivered using the assumption that the proton relative biological effectiveness (RBE) relative to photons is 1.1. This assumption ignores strong experimental evidence that suggests the RBE varies along the treatment field, i.e. with linear energy transfer (LET) and with tissue type. A recent review study collected over 70 experimental reports on proton RBE, providing a comprehensive dataset for predicting RBE for cell survival. Using this dataset we developed a model to predict proton RBE based on dose, LET and the ratio of the linear-quadratic model parameters for the reference radiation (α/β)x, as the tissue specific parameter. Methods and Materials The relationship of the RBE on dose, dose average LET (LETd) and (α/β)x was explored using 287 experimental data points. A RBE model based on the linear quadratic model was derived from a nonlinear regression fitting to the data. Results The proposed model predicts that the RBE increases with increasing LETd and decreases with increasing (α/β)x. The model additionally predicts a decrease in RBE with increasing dose. Conclusions The proposed phenomenological RBE model is derived using the most comprehensive collection of proton RBE experimental data to date. The model agrees with previous theoretical predictions on the relationship between RBE, LETd and (α/β)x and also makes predictions on the relationship between RBE and dose. The proposed model shows a relationship between both α and β with LETd. Previously published phenomenological models, based on a limited data set, may have to be revised.

show abstract

Section: Methodsmentioning

confidence: 99%

A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all publishedin vitrocell survival data

2015

View full text Add to dashboard Cite

show abstract

“…Furthermore, a wide range of non-surgical treatment modalities is used, such as chemotherapy, targeted therapy, immunotherapy, and radiation therapy [ 6 ]. Radical re-excision of the tumour bed in the case of cutaneous malignant melanoma is a central part of the surgical treatment.…”

Section: Introductionmentioning

confidence: 99%

Re-excision within a radius of 2 cm in patients with melanoma of the skin – sufficient for local oncological radicalness

et al. 2020

View full text Add to dashboard Cite

Introduction: Malignant melanoma is one of the most malignant tumours in the human body. Radical re-excision of the tumour bed is a principal part of its surgical treatment. We aim to test the hypothesis that the re-excision with a 2 cm margin in all directions to the scar from the previous biopsy of the primary tumour provides sufficient local control in patients with this disease. Material and methods: This is a prospective descriptive study using STROBE methods, including all 151 patients with malignant melanoma of the skin, diagnosed and treated at the

show abstract

“…On the contrary, few works have been published about cells exposed to proton radiation and most of them refer to exposure at high proton dose (from 1 Gy up to more than 10 Gy), as expected, because the authors investigated radiosensitivity of tumor cell lines. These works, based on biological assays, reported that protons have a larger relative biological effectiveness (RBE) than photons (Keta et al 2014) and the RBE value increases as the cell position on the Spread Out Bragg Peak (SOBP) moves distally (Chaudhary et al 2014;Matsumoto et al 2014;Hojo et al 2017). In addition, Fourier Transform Infrared Spectroscopy measurements revealed chromatin fragmentation in adenocarcinoma PC-3 cells following proton irradiation (Lipiec et al 2014).…”

Section: Introductionmentioning

confidence: 99%

Raman spectroscopy monitoring of MCF10A cells irradiated by protons at clinical doses

Lasalvia

Perna

Manti

et al. 2019

International Journal of Radiation Biology

View full text Add to dashboard Cite

Purpose: Proton therapy has been recently proposed as a radiotherapy form for breast cancer treatment in view of its potentially decreased normal-tissue toxicity compared with conventional photon-based radiotherapy. However, the risks for the healthy tissue cannot be completely eliminated. In the present study, the suitability of Raman spectroscopy to monitor the radiosensitivity of normal cells exposed to clinical proton beam was investigated. Materials and methods: MCF10A normal human breast cells were irradiated at two different proton doses: 0.5 Gy and 4 Gy. They were fixed immediately after irradiation and measured by means of Raman spectroscopy technique. The obtained data were analyzed both by evaluating the intensity ratio of specific Raman spectral peaks and through Multivariate Distance Matrix Regression technique. Results: Certain Raman peaks associated with DNA showed a systematic suppression at both dose levels. In particular, the intensity of a Raman peak at 784 cm À1 , related to a stretching mode inside the phosphate group of DNA, is very sensitive to the proton beam exposure, even at the lowest investigated dose. Therefore, it could be considered as a spectral marker of cytogenetic damage. Conclusions: The obtained results are encouraging for the future of Raman spectroscopy in radiobiology research, particularly for improving risk assessment in the field of proton radiotherapy. Specifically, these findings validate Raman spectroscopy to measure biological response in human breast cells exposed to standard proton therapy doses used in clinical setting.

show abstract

Radiosensitivity of human ovarian carcinoma and melanoma cells to γ-rays and protons

Cited by 11 publications

References 27 publications

A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all publishedin vitrocell survival data

A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all publishedin vitrocell survival data

Re-excision within a radius of 2 cm in patients with melanoma of the skin – sufficient for local oncological radicalness

Raman spectroscopy monitoring of MCF10A cells irradiated by protons at clinical doses

Contact Info

Product

Resources

About